SCB-2019

SCB-2019
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular
Identifiers
CAS Number
DrugBank

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies.[2] Positive results of Phase I trials for the vaccine were published in The Lancet[3] and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021.[4] In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.[5]

SCB-2019 is being funded by CEPI as part of COVAX[6] and has received advanced purchase orders from GAVI for 400 million doses,[7] with production to begin in 2021.[8]

  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ "Chinese biotech firm Clover signs deal to make millions of vaccines". South China Morning Post. 30 June 2021. Retrieved 8 July 2021.
  3. ^ Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al. (February 2021). "Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial". Lancet. 397 (10275): 682–694. doi:10.1016/S0140-6736(21)00241-5. PMC 7906655. PMID 33524311.
  4. ^ Cite error: The named reference :2 was invoked but never defined (see the help page).
  5. ^ Liu R (22 September 2021). "Clover's vaccine 67% effective against COVID, 79% against Delta variant in large trial". Reuters. Retrieved 22 September 2021.
  6. ^ Rogers J (July 2021). "From lab to potential jab: Clover's COVID-19 vaccine story". CEPI. Retrieved 8 July 2021.
  7. ^ "Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX". www.gavi.org. Retrieved 8 July 2021.
  8. ^ "Clover's COVID-19 shot tames delta in pivotal study, delivering boost to global vaccination campaign". FierceBiotech. 22 September 2021. Retrieved 22 September 2021.